![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead’s Sovaldi Facing Another International Patent Challenge, This Time in Europe
Gilead’s Sovaldi Facing Another International Patent Challenge, This Time in Europe
![](https://www.fdanews.com/ext/resources/test/Drug-Images2/BalancingScaleGreen.gif?t=1436288370&width=432)
Gilead’s pricey hepatitis C blockbuster Sovaldi is facing another international patent challenge, this time by a French nonprofit.
Médecins du Monde, or Doctors of the World, said that it had filed a challenge to Sovaldi (sofosbuvir) with the European Patent Office. While Sovaldi is an important development in hepatitis C treatment, it is not sufficiently innovative to deserve patent protection, the group claims.
The challenge mirrors one brought in India by the Initiative for Medicines, Access & Knowledge.
MDM maintains that branded Sovaldi, priced at $84,000 for a full 12-week treatment in the U.S., is far too costly and is forcing drug rationing. The group wants generic competition to drive down Sovaldi’s cost.
Gilead declined a request for comment. The company is actively fighting the decision by India’s patent office to deny one of the patents it sought for Sovaldi, and won a temporary victory when that decision was thrown out by the Delhi high court late last month on procedural grounds. — Bryan Koenig
Upcoming Events
-
11Jul
-
18Jul
-
21Oct